

# Jakob D Rudzki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1419540/publications.pdf>

Version: 2024-02-01

9  
papers

77  
citations

1937685  
4  
h-index

1588992  
8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

112  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PIP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases. <i>Clinical Lung Cancer</i> , 2019, 20, e247-e250.	2.6	24
2	Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2248-2260.	1.4	20
3	ASCO 2018 NSCLC highlights—combination therapy is key. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 266-271.	0.5	12
4	The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. <i>Cancers</i> , 2021, 13, 4701.	3.7	6
5	Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 27-31.	0.5	5
6	Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 225-229.	0.5	4
7	Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?. <i>Expert Review of Hematology</i> , 2011, 4, 153-159.	2.2	3
8	AML—is it time to drive a CAR(-T)?. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 50-54.	0.5	3
9	CAR(-T)s are on the road. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 3-4.	0.5	0